Rosacea: A review of current topical, systemic and light based therapies

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 6, 2009, Pages 673-688

  Kennedy Carney, C ^a   Cantrell, W ^a   Elewski, B E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Anti inflammatory agents; Phototherapy; Rosacea, etiology

Indexed keywords

ANTIINFLAMMATORY AGENT; AVOBENZONE; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CALCINEURIN INHIBITOR; CATHELICIDIN; CLINDAMYCIN; CORTICOSTEROID; COSMETIC; DOXYCYCLINE; ERYTHROMYCIN; GLYCYRRHIZA EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; ISOTRETINOIN; IVERMECTIN; LICOCHALCONE A; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; PERMETHRIN; PIMECROLIMUS; RETINOIC ACID; RETINOID; ROSAC; ROSASAL; SULFACETAMIDE; SUNSCREEN; TACROLIMUS; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL FEATURE; DEMODEX; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATORY DISEASE; NEODYMIUM LASER; OXIDATIVE STRESS; PATHOGENESIS; PHOTOTHERAPY; PREVALENCE; PULSED DYE LASER; REMISSION; REVIEW; RISK FACTOR; ROSACEA; SKIN CARE; STAPHYLOCOCCUS EPIDERMIDIS; SUNLIGHT PROTECTION; TELANGIECTASIA; TOPICAL TREATMENT;

EID: 77949591964     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Tanzi E, Weinberg J. The ocular manifestations of Rosacea. Cutis 2001;68:112-4.
2. Wilkin J, Dahl M, Detmar M, Drake L, Liang M, Odom R et al. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002;46:584-7.
3. Milikan LE. Rosacea as an inflammatory disorder: a unifying theory? Cutis. 2004;73(Suppl 1):5-8.
4. Bikowski J, Goldman M. Rosacea: where are we now. J Drugs Dermatol 2003;3:251-61.
5. Del Rosso J. on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis 2006;78:97-100.
6. Culp B, Scheinfeld N. Rosacea: a review. P&T 2009;34:38-45.
7. Buechner S. Rosacea: an update. Dermatol 2005;210:100-8.
8. Kyriakis K, Palamaras I, Terzoudi S, Emmanuelides S, Michailides C, Pagana G. Epidemiologic aspects of rosacea. J Am Acad Dermatol 2005;53:918-9.
9. Aroni K, Tsagroni E, Kavantzas N, Patsouris E, Ioannidis E. A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 2008;300:125-31.
10. Heymann W. Rosacea subtype-directed therapy. J Am Acad Dermatol 2004;51:90-2.
11. Milikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed 2003;2:43-7.
12. Crawford G, Pelle M, James W. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004;51:327-41.
13. Lacey N, Delaney S, Kavanagh K, Powell F. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol 2007;157:474-81.
14. Powell F. Rosacea and the pilosebaceous follicle. Cutis 2004;74(3 Suppl):9-12, 32-4.
15. Baldwin H. Systemic therapy for rosacea. Skin Therapy Lett 2007;12:1-5.
16. Korting H, Schollmann C. Current topical and systemic approaches to treatment of rosacea. JEADV 2009;23:876-82.
17. Wilkin J. A role for vascular pathogenic mechanisms in rosacea: implications for patient care. Cutis 2008;82:100-2.
18. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975-80.
19. Dahl M, Ross A, Schlievert P. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol 2004;50:266-72.
20. Tisma V, Basta-Juzbasic A, Jaganjac M, Brcic L, Dobric I, Lipozencic J et al. Oxidative stress and ferritin expression in the skin of patients with rosacea. J Am Acad Dermatol 2009;60:270-6.
21. Wilkin J, Dahl M, Detmar M, Drake L, Liang M, Odom R et al. Standard grading system for rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2004;50:907-12.
22. Akpek E, Merchant A, Pinar V, Foster C. Ocular rosacea: patient characteristics and follow-up. Ophthalmology 1997 Nov;104:1863-7.
23. Nally J, Berson D. Topical therapies for rosacea. J Drugs Dermatol 2006;5:23-6.
24. Draelos Z. Treating beyond the histology of rosacea. Cutis 2004;74(3 Suppl):28-31, 2-4.
25. Pelle M, Crawford G, James W. Rosacea: D. Therapy. J Am Acad Dermatol 2004;51:499-512; quiz 3-4.
26. Del Rosso J. Adjunctive skin care in the management of rosacea: cleansers, moisturizers, and photoprotectants. Cutis 2005;75(3 Suppi):17-21; discussion 33-6.
27. Nichols K, Desai N, Lebwohl M. Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. Cutis 1998;61:344-6.
28. Tan J, Girard C, Krol A, Murray H, Papp K, Poulin Y et al. Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. J Cutan Med Surg 2002;6:529-34.
29. Draelos Z. The effect of Cetaphil Gentle Skin Cleanser on the skin barrier of patients with rosacea. Cutis 2006;77(4 Suppl):27-33.
30. Laquieze S, Czernielewski J, Baltas E. Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. J Dermatolog Treat 2007;18:158-62.
31. Wu J. Treatment of rosacea with herbal ingredients. J Drugs Dermatol. 2006;5:29-32.
32. Weber T, Ceilley R, Buerger A, Kolbe L, Trookman N, Rizer R et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A. J Cosmet Dermatol 2006;5:227-32.
33. Thornfeldt C. Incorporating natural therapy for rosacea. Practical Dermatol 2008;5:40-3.
34. Trumbore M, Goldstein J, Gurge R. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol 2009;8:299-304.
35. Del Rosso J. A status report on the medical management of rosacea: focus on topical therapies. Cutis 2002;70:271-5.
36. Torok H, Webster G, Dunlap F, Egan N, Jarratt M, Stewart D. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis 2005;75:357-63.
37. McClellan K, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol 2000;1:191-9.
38. Wolf JJ, Del Rosso J. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis 2007;79:73-80.
39. Dahl M, Jarratt M, Kaplan D, Tuley M, Baker M. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol 2001;45:723-30.
40. Yoo J, Reid D, Kimball A. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol 2006;5:317-9.
41. Colón L, Johnson L, Gottschalk R. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis 2007;79:317-21.
42. Draelos Z. Assessment of skin barrier function in rosacea patients with a novel 1% metronidazole gel. J Drugs Dermatol 2005;4:557-62.
43. Conde J, Yelverton C, Balkrishnan R, Fleischer AJ, Feldman S. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 2007;6:495-8.
44. Dahl M, Katz H, Krueger G, Millikan L, Odom R, Parker F et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998;134:679-83.
45. Frampton J, Wagstaff A. Azelaic acid 15% gel: in the treatment of papulopustular rosacea. Am J Clin Dermatol 2004;5:57-64.
46. Gupta A, Gover M. Azelaic acid (15% gel) in the treatment of acne rosacea. Int J Dermatol 2007;46:533-8.
47. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003;48:836-45.
48. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol 1999;79:456-9.
49. Elewski B, Thiboutot D. A clinical overview of azelaic acid. Cutis 2006;77(2 Suppl):12-6.
50. Draelos Z. The rationale for advancing the formulation of azelaic acid vehicles. Cutis 2006;77(2 Suppl):7-11.
51. Liu R, Smith M, Basta S, Farmer E. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol 2006;142:1047-52.
52. Elewski B, Fleischer AJ, Pariser D. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 2003;139:1444-50.
53. Ziel K, Yelverton C, Balkrishnan R, Feldman S. Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. J Drugs Dermatol 2005;4:727-31.
54. Wolf JJ, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis 2006;77(4 Suppl):3-11.
55. Elewski B. Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%. Cutis 2007;79:57-8; author reply 8.
56. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999;40(6 Pt 1):961-5.
57. Oztürkcan S, Ermertcan A, Sahin M, Afflar F. Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. J Dermatol 2004;31:610-7.
58. McHugh R, Rice A, Sangha N, McCarty M, Utterback R, Rohrback J et al. A topical azithromycin preparation for the treatment of acne vulgaris and rosacea. J Dermatolog Treat 2004;15:295-302.
59. Nghiem P, Pearson G, Langley R. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002;46:228-41.
60. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001;44:995-8.
61. Chu C. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005;152:396-9.
62. Chu C. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. J Eur Acad Dermatol Venereol 2007;21:484-90.
63. Lee D, Li K, Suh D. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. Br J Dermatol 2008;158:1069-76.
64. Bamford J, Elliott B, Haller I. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004;50:107-8.
65. Crawford K, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005;4:147-50.
66. Weissenbacher S, Merkl J, Hildebrandt B, Wollenberg A, Braeutigam M, Ring J et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007;156:728-32.
67. Karabulut A, Izol Serel B, Eksioglu H. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. J Eur Acad Dermatol Venereol 2008;22:729-34.
68. Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS, Cinar S. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol 2009 Jul 6.[Epub ahead of print]
69. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging 2006;1:327-48.
70. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997;53:358-88.
71. Vienne MP, Ochando N, Borrel MT, Gall Y, Lauze C, Dupuy P. Retinaldehyde alleviates rosacea. Dermatology 1999;199(Suppl 1):53-6.
72. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol 1994;130:319-24.
73. Koçak M, Ya li S, Vahapo lu G, Ekflio lu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 2002;205:265-70.
74. Allen K, Davis C, Billings S, Mousdicas N. Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis 2007;80:149-51.
75. Sapadin A, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-65.
76. Webster G, Del Rosso J. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007;25:133-5, v.
77. Del Rosso J. Recently approved systemic therapies for acne vulgaris and rosacea. Cutis 2007;80:113-20.
78. Del Rosso J, Webster G, Jackson M, Rendon M, Rich P, Torok H et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007;56:791-802.
79. Del Rosso J, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008;7:573-7.
80. Fowler JJ. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 2007;6:641-5.
81. Thiboutot D, Fleischer A, Del Rosso J, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol 2009;8:639-48.
82. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008;47:284-8.
83. Bakar O, Demircay Z, Yuksel M, Haklar G, Sanisoglu Y. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol 2007;32:197-200.
84. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 1997;36:942-6.
85. Torresani C. Clarithromycin: a new perspective in rosacea treatment. Int J Dermatol 1998;37:347-9.
86. Elewski BE. A novel treatment for acne vulgaris and rosacea. J Eur Acad Dermatol Venereol 2000;14:423-4.
87. Modi S, Hailing M, Rosen T. Azithromycin as an alternative rosacea therapy when tetracyclines prove problematic. J Drugs Dermatol 2008;7:898-9.
88. Wienbren M, Perinpanayagam R, Camba L, Lee C. Convulsions and encephalopathy in a patient with leukemia after treatment with metronidazole. J Clin Pathol 1985;38:1076.
89. Saihan E, Burton J. A double-blind trial of metronidazole versus Oxytetracycline therapy for rosacea. Br J Dermatol 1980;102:443-5.
90. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998;134:884-5.
91. Hofer T. Continuous 'microdose' isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol 2004;29:204-5.
92. Butterwick K, Butterwick L, Han A. Laser and light therapies for acne rosacea. J Drugs Dermatol 2006;5:35-9.
93. Clark S, Lanigan S, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci 2002;17:26-33.
94. Lowe N, Behr K, Fitzpatrick R, Goldman M, Ruiz-Esparza J. Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema. J Dermatol Surg Oncol 1991;17:522-5.
95. Tan S, Bialostocki A, Armstrong J. Pulsed dye laser therapy for rosacea. Br J Plast Surg 2004;57:303-10.
96. Jasim Z, Woo W, Handley J. Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold. Dermatol Surg 2004;30:37-40.
97. Tan S, Tope W. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol 2004;51:592-9.
98. Bernstein E, Kligman A. Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers Surg Med 2008;40:233-9.
99. Laube S, Lanigan S. Laser treatment of rosacea. J Cosmet Dermatol 2002;1:188-95.
100. Taub A. Treatment of rosacea with intense pulsed light. J Drugs Dermatol 2003;2:254-9.
101. Mark K, Sparacio R, Voigt A, Marenus K, Sarnoff D. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg 2003;29:600-4.
102. Papageorgiou P, Clayton W, Norwood S, Chopra S, Rustin M. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol 2008;159:628-32.
103. Schroeter C, Haaf-von Below S, Neumann H. Effective treatment of rosacea using intense pulsed light systems. Dermatol Surg 2005;31:1285-9.
104. Jørgensen G, Hedelund L, Haedersdal M. Long-pulsed dye laser versus intense pulsed light for photodamaged skin: a randomized split-face trial with blinded response evaluation. Lasers Surg Med 2008;40:293-9.
105. Neuhaus I, Zane L, Tope W. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg 2009;35:920-8.